Will vaccine regulatory uncertainty chill innovation? Pharma execs sound off.

Moderna’s clash with U.S. health agencies over its flu shot reflects a difficult time for vaccinemakers, but many are still playing the waiting game.

By Michael Gibney • Feb. 19, 2026

Ovid takes another big swing in neuroscience under a new CEO

After multiple setbacks, the company is chasing a CNS target it believes has “revolutionary” potential.

By Meagan Parrish • Feb. 13, 2026

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

Sanofi, looking for more ‘rigor,’ swaps CEO Hudson for ex-Merck KGaA chief

The move drew skepticism from investors despite multiple recent research setbacks that have left questions about Sanofi’s ability to confront Dupixent’s looming patent expiration.

By Kristin Jensen • Feb. 13, 2026

In a tough market, biotechs can be their own worst enemy

Even with sound science, startups can struggle to make their candidates go the distance.

By Alexandra Pecci • Feb. 10, 2026

Bayer sets the stage for a pharma comeback

The pharma giant’s drug sales haven’t wowed in recent years. But that could soon change.

By Meagan Parrish • Feb. 6, 2026

Big Pharma CEOs set sights on massive growth in years to come

The CEOs at Johnson & Johnson, Pfizer and Merck have big plans for future revenue even as they face difficult odds in the here and now.

By Michael Gibney • Feb. 5, 2026

Pharma’s outlook in 2026: Smoother sailing ahead?

After a turbulent year, the industry has a clearer picture of its new landscape and how to navigate the challenges and opportunities ahead. 

By Meagan Parrish • Jan. 30, 2026

The clinical candidates pharma execs are tracking

Industry leaders at JPM this week revealed which up-and-coming assets they’re watching from other companies in oncology and neuroscience.

By Meagan Parrish • Jan. 16, 2026

PharmaVoice’s Crystal Ball: What’s next for AI and drug R&D

Industry execs foresee drug innovation and AI breakthroughs in 2026.

By Meagan Parrish • Jan. 9, 2026

Billionaire Sean Parker has already shaken up cancer R&D. Can his nonprofit fix the funding gap?

The entrepreneur’s cancer institute is striving to be the financial glue for an embattled research community while going beyond therapies and creating cures.

By Michael Gibney • Jan. 8, 2026

The wellness industry is HHS’ new belle of the ball

Congressional leaders and health experts are sounding the alarm about potential conflicts of interest among the agency’s new leaders.

By Kelly Bilodeau • Jan. 8, 2026

C-suite priorities give a sneak peek into AI’s pharma future

While some are still leery of the technology, leaders see AI as a way to boost efficiency and cut costs.

By Kelly Bilodeau • Jan. 7, 2026

PharmaVoice’s Crystal Ball: Market and policy forces shaping the industry

How pharma leaders believe the regulatory and investment market landscape will change in 2026. 

By Meagan Parrish • Jan. 6, 2026

Biopharma CEO optimism is wavering in the US

The overall leadership outlook was positive in a recent survey but varied between executives in the U.S. and those overseas.

By Kelly Bilodeau • Dec. 22, 2025

Biogen’s CIO is betting on a tech and AI overhaul to ‘pave the highways’ toward growth

Guy Hadari discusses how his role has changed with the introduction of new technologies, and what that means for Biogen’s future.

By Michael Gibney • Dec. 19, 2025

5 CDER directors in one year? Turnover threatens ‘institutional memory’ at US health agencies.

Rapid movement among regulators’ top brass has contributed to an inconsistent strategic direction — but there’s hope in bureaucracy.

By Michael Gibney • Dec. 16, 2025

Unifying life sciences insights to accelerate enterprise value

Unified insights yield enhanced organizational strategic value, unlocking cross-functional innovation and reducing costs.

By Fabrice Dussol, AplusA Research, Head of US Commercial Strategy, Lynn Ricker, KnowVanta, Principal & Founder, and Diana Pohle, BioMarin Pharmaceuticals, Head of Business Insights & Analytics • Dec. 8, 2025

BeOne brought Brukinsa to the blood cancer mountaintop. Can it hit those heights again?

The company’s chief medical officer discusses its trajectory with the blockbuster Brukinsa and its strong hematology pipeline.

By Michael Gibney • Dec. 4, 2025

A drugmaker charts a path through pharma’s ethical minefields

As the science behind pharma breakthroughs becomes more complex, bioethicists are helping companies navigate moral quandaries.

By Kelly Bilodeau • Dec. 1, 2025

Pharma faces a critical ‘turning point’ in 2026, years in the making

While Trump’s manufacturing and pricing deals with pharma shape the industry’s future, COVID’s impact still ripples throughout the health landscape.

By Michael Gibney • Nov. 21, 2025

How do Big Pharma employees rate their CEOs?

There are many ways to steer the ship as the top exec of a large pharma company. Here are the ones employees approve of the most — as well as those who could polish their image a little more.

By Alexandra Pecci • Nov. 20, 2025

RNAi looked doomed to fail — until Alnylam’s science chief found a way

Kevin Fitzgerald, Alnylam Pharmaceuticals’ chief scientific officer, reveals the hard times that led to RNAi success, and what it takes to pave new roads in biotech.

By Michael Gibney • Nov. 13, 2025

After a lackluster first drug launch, a new CEO is finding Geron’s commercial footing

Harout Semerjian, whose pedigree includes launching the Novartis cancer blockbuster Gleevec, is aiming to boost awareness about Geron’s Rytelo to give it momentum.

By Alexandra Pecci • Nov. 12, 2025

Why Pfizer and Novo are duking it out over weight loss startup Metsera

A brutal bidding war between two industry giants over a clinical-stage drugmaker is a sign of the weight loss arena’s high stakes.

By Michael Gibney • Nov. 6, 2025

How Trump’s do-or-die agenda is impacting Big Pharma’s CEO chatter

Among tariffs, pricing policies and ongoing negotiations, pharma leaders can’t help but address their dealings with the Trump administration in third-quarter earnings reports.

By Michael Gibney • Oct. 30, 2025